Skip to main content

Model Based on Age, Routine Lab Tests Predicts Atherosclerotic CVD Accurately

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 12, 2023.

By Elana Gotkine HealthDay Reporter

MONDAY, Dec. 11, 2023 -- The CANHEART (Cardiovascular Health in Ambulatory Care Research Team) Lab Models can predict atherosclerotic cardiovascular disease (ASCVD) with similar accuracy to more complex models, according to a study published online Dec. 12 in the Annals of Internal Medicine.

Maneesh Sud, M.D., Ph.D., from Sunnybrook Health Sciences Centre in Toronto, and colleagues developed and validated sex-specific prediction models for ASCVD using age and routine laboratory tests in a derivation and internal validation cohort of 2,160,497 women and 1,833,147 men aged 40 to 75 years without cardiovascular disease from April 2009 to December 2015 and an external validation cohort of 31,697 primary care patients from January 2010 to December 2014. Prediction model performance was compared to that of the pooled cohort equations (PCEs).

The researchers found that the sex-specific models were well calibrated; for both sexes, the relative differences were less than 1 percent between the mean predicted and observed risk. The C-statistics were 0.77 and 0.71 in women and men, respectively. A relative difference of less than 14 percent was seen in external validation in primary care patients; in both sexes, there was an absolute difference of less than 0.3 percentage points in mean predicted and observed risks. For the laboratory models, the C-statistics were 0.72 for both sexes and did not differ significantly from those of the PCEs for women or men.

"Future studies are needed to determine whether automating these models in daily practice improves prescribing of preventive treatments according to clinical practice guidelines," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM

FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...

DNA Methylation-Based Epigenetic Age Mediates Link Between LE8 Score, CVD

WEDNESDAY, May 29, 2024 -- The associations between Life's Essential 8 (LE8) and cardiovascular health are mediated by DNA methylation-based epigenetic age, according to a study...

Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease

TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.